InvestorsHub Logo
Followers 14
Posts 2778
Boards Moderated 0
Alias Born 12/23/2014

Re: None

Thursday, 12/09/2021 11:19:53 AM

Thursday, December 09, 2021 11:19:53 AM

Post# of 459
i listened to the call. The drivers for growth remain the same. Subg is cheaper, more convenient and has less patient adverse reactions because medication levels remain more even in the blood level. The company continues to work with/partner with drug companies in a mutually beneficial symbiotic relationship.

Bottom line is a question of execution. And time will tell.

The guidance given seems conservative. I believe KORU medical has a quality, dedicated professional team. I expect some analyst will release upgrade evaluations with higher stock target price.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KRMD News